Titre : Neurofibres

Neurofibres : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Neurofibres : Questions médicales les plus fréquentes", "headline": "Neurofibres : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Neurofibres : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-06", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Neurofibres" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Neurones", "url": "https://questionsmedicales.fr/mesh/D009474", "about": { "@type": "MedicalCondition", "name": "Neurones", "code": { "@type": "MedicalCode", "code": "D009474", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Neurofibres adrénergiques", "alternateName": "Adrenergic Fibers", "url": "https://questionsmedicales.fr/mesh/D000320", "about": { "@type": "MedicalCondition", "name": "Neurofibres adrénergiques", "code": { "@type": "MedicalCode", "code": "D000320", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.075" } } }, { "@type": "MedicalWebPage", "name": "Neurofibres autonomes postganglionnaires", "alternateName": "Autonomic Fibers, Postganglionic", "url": "https://questionsmedicales.fr/mesh/D001338", "about": { "@type": "MedicalCondition", "name": "Neurofibres autonomes postganglionnaires", "code": { "@type": "MedicalCode", "code": "D001338", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.100" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Neurofibres sympathiques postganglionnaires", "alternateName": "Sympathetic Fibers, Postganglionic", "url": "https://questionsmedicales.fr/mesh/D017779", "about": { "@type": "MedicalCondition", "name": "Neurofibres sympathiques postganglionnaires", "code": { "@type": "MedicalCode", "code": "D017779", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.100.800" } } } ] }, { "@type": "MedicalWebPage", "name": "Axones", "alternateName": "Axons", "url": "https://questionsmedicales.fr/mesh/D001369", "about": { "@type": "MedicalCondition", "name": "Axones", "code": { "@type": "MedicalCode", "code": "D001369", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.145" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Segment initial de l'axone", "alternateName": "Axon Initial Segment", "url": "https://questionsmedicales.fr/mesh/D000071040", "about": { "@type": "MedicalCondition", "name": "Segment initial de l'axone", "code": { "@type": "MedicalCode", "code": "D000071040", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.145.250" } } }, { "@type": "MedicalWebPage", "name": "Cônes de croissance", "alternateName": "Growth Cones", "url": "https://questionsmedicales.fr/mesh/D020439", "about": { "@type": "MedicalCondition", "name": "Cônes de croissance", "code": { "@type": "MedicalCode", "code": "D020439", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.145.375" } } }, { "@type": "MedicalWebPage", "name": "Fibres moussues de l'hippocampe", "alternateName": "Mossy Fibers, Hippocampal", "url": "https://questionsmedicales.fr/mesh/D019599", "about": { "@type": "MedicalCondition", "name": "Fibres moussues de l'hippocampe", "code": { "@type": "MedicalCode", "code": "D019599", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.145.438" } } }, { "@type": "MedicalWebPage", "name": "Terminaisons présynaptiques", "alternateName": "Presynaptic Terminals", "url": "https://questionsmedicales.fr/mesh/D017729", "about": { "@type": "MedicalCondition", "name": "Terminaisons présynaptiques", "code": { "@type": "MedicalCode", "code": "D017729", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.145.750" } } }, { "@type": "MedicalWebPage", "name": "Collatéraux de Schaffer", "alternateName": "Schaffer Collaterals", "url": "https://questionsmedicales.fr/mesh/D000094282", "about": { "@type": "MedicalCondition", "name": "Collatéraux de Schaffer", "code": { "@type": "MedicalCode", "code": "D000094282", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.145.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Neurofibres cholinergiques", "alternateName": "Cholinergic Fibers", "url": "https://questionsmedicales.fr/mesh/D002799", "about": { "@type": "MedicalCondition", "name": "Neurofibres cholinergiques", "code": { "@type": "MedicalCode", "code": "D002799", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.234" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Neurofibres autonomes préganglionnaires", "alternateName": "Autonomic Fibers, Preganglionic", "url": "https://questionsmedicales.fr/mesh/D001339", "about": { "@type": "MedicalCondition", "name": "Neurofibres autonomes préganglionnaires", "code": { "@type": "MedicalCode", "code": "D001339", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.234.060" } } }, { "@type": "MedicalWebPage", "name": "Neurofibres parasympathiques postganglionnaires", "alternateName": "Parasympathetic Fibers, Postganglionic", "url": "https://questionsmedicales.fr/mesh/D017777", "about": { "@type": "MedicalCondition", "name": "Neurofibres parasympathiques postganglionnaires", "code": { "@type": "MedicalCode", "code": "D017777", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.234.700" } } } ] }, { "@type": "MedicalWebPage", "name": "Gaine de myéline", "alternateName": "Myelin Sheath", "url": "https://questionsmedicales.fr/mesh/D009186", "about": { "@type": "MedicalCondition", "name": "Gaine de myéline", "code": { "@type": "MedicalCode", "code": "D009186", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.512.560" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gaine de Schwann", "alternateName": "Neurilemma", "url": "https://questionsmedicales.fr/mesh/D009441", "about": { "@type": "MedicalCondition", "name": "Gaine de Schwann", "code": { "@type": "MedicalCode", "code": "D009441", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.512.560.550" } } }, { "@type": "MedicalWebPage", "name": "Noeuds de Ranvier", "alternateName": "Ranvier's Nodes", "url": "https://questionsmedicales.fr/mesh/D011901", "about": { "@type": "MedicalCondition", "name": "Noeuds de Ranvier", "code": { "@type": "MedicalCode", "code": "D011901", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.512.560.700" } } } ] }, { "@type": "MedicalWebPage", "name": "Neurofibres non-myélinisées", "alternateName": "Nerve Fibers, Unmyelinated", "url": "https://questionsmedicales.fr/mesh/D036421", "about": { "@type": "MedicalCondition", "name": "Neurofibres non-myélinisées", "code": { "@type": "MedicalCode", "code": "D036421", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.671.501.756" } } } ], "about": { "@type": "MedicalCondition", "name": "Neurofibres", "alternateName": "Nerve Fibers", "code": { "@type": "MedicalCode", "code": "D009412", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Z V Surnina", "url": "https://questionsmedicales.fr/author/Z%20V%20Surnina", "affiliation": { "@type": "Organization", "name": "Krasnov Research Institute of Eye Diseases, Moscow, Russia." } }, { "@type": "Person", "name": "S E Avetisov", "url": "https://questionsmedicales.fr/author/S%20E%20Avetisov", "affiliation": { "@type": "Organization", "name": "Krasnov Research Institute of Eye Diseases, Moscow, Russia." } }, { "@type": "Person", "name": "Yao-Chuan Chang", "url": "https://questionsmedicales.fr/author/Yao-Chuan%20Chang", "affiliation": { "@type": "Organization", "name": "Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 11030, USA." } }, { "@type": "Person", "name": "Stavros Zanos", "url": "https://questionsmedicales.fr/author/Stavros%20Zanos", "affiliation": { "@type": "Organization", "name": "Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 11030, USA. Electronic address: szanos@northwell.edu." } }, { "@type": "Person", "name": "Elçin Tunçkol", "url": "https://questionsmedicales.fr/author/El%C3%A7in%20Tun%C3%A7kol", "affiliation": { "@type": "Organization", "name": "Bernstein Center for Computational Neuroscience Berlin, Humboldt-Universität zu Berlin, Philippstrasse 13, Haus 6, Berlin, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Tocolytics for delaying preterm birth: a network meta-analysis (0924).", "datePublished": "2022-08-10", "url": "https://questionsmedicales.fr/article/35947046", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD014978.pub2" } }, { "@type": "ScholarlyArticle", "name": "Bayesian unanchored additive models for component network meta-analysis.", "datePublished": "2022-07-17", "url": "https://questionsmedicales.fr/article/35844085", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/sim.9520" } }, { "@type": "ScholarlyArticle", "name": "Pharmacological treatments in panic disorder in adults: a network meta-analysis.", "datePublished": "2023-11-28", "url": "https://questionsmedicales.fr/article/38014714", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD012729.pub3" } }, { "@type": "ScholarlyArticle", "name": "Thresholds for surfactant use in preterm neonates: a network meta-analysis.", "datePublished": "2022-12-09", "url": "https://questionsmedicales.fr/article/36600484", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/archdischild-2022-324184" } }, { "@type": "ScholarlyArticle", "name": "Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.", "datePublished": "2022-09-14", "url": "https://questionsmedicales.fr/article/36189211", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.1006860" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Neurones", "item": "https://questionsmedicales.fr/mesh/D009474" }, { "@type": "ListItem", "position": 4, "name": "Neurofibres", "item": "https://questionsmedicales.fr/mesh/D009412" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Neurofibres - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Neurofibres", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Neurofibres", "description": "Comment diagnostiquer une neuropathie ?\nQuels tests pour évaluer les neurofibres ?\nLes IRM sont-elles utiles pour les neurofibres ?\nQuels signes indiquent une atteinte des neurofibres ?\nComment évaluer la conduction nerveuse ?", "url": "https://questionsmedicales.fr/mesh/D009412?mesh_terms=Network+Meta-Analysis&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Neurofibres", "description": "Quels sont les symptômes d'une neuropathie ?\nComment se manifeste une neuropathie périphérique ?\nLes symptômes varient-ils selon le type de neurofibres ?\nPeut-on avoir des symptômes sans lésions visibles ?\nLes symptômes s'aggravent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D009412?mesh_terms=Network+Meta-Analysis&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Neurofibres", "description": "Comment prévenir les neuropathies ?\nL'exercice régulier aide-t-il à prévenir les neuropathies ?\nLes habitudes alimentaires influencent-elles les neurofibres ?\nFumer augmente-t-il le risque de neuropathie ?\nLe stress a-t-il un impact sur les neurofibres ?", "url": "https://questionsmedicales.fr/mesh/D009412?mesh_terms=Network+Meta-Analysis&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Neurofibres", "description": "Quels traitements existent pour les neuropathies ?\nLes médicaments peuvent-ils soulager la douleur nerveuse ?\nLa physiothérapie aide-t-elle les patients ?\nQuand envisager une intervention chirurgicale ?\nLes traitements sont-ils efficaces pour tous ?", "url": "https://questionsmedicales.fr/mesh/D009412?mesh_terms=Network+Meta-Analysis&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Neurofibres", "description": "Quelles complications peuvent survenir avec une neuropathie ?\nLa neuropathie peut-elle entraîner des amputations ?\nLes troubles de la marche sont-ils une complication ?\nPeut-on développer une dépression à cause de la neuropathie ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D009412?mesh_terms=Network+Meta-Analysis&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Neurofibres", "description": "Quels sont les principaux facteurs de risque de neuropathie ?\nL'âge influence-t-il le risque de neuropathie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe diabète est-il un facteur de risque majeur ?\nLes carences nutritionnelles augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D009412?mesh_terms=Network+Meta-Analysis&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une neuropathie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un examen neurologique, des tests électrophysiologiques et des analyses sanguines sont utilisés." } }, { "@type": "Question", "name": "Quels tests pour évaluer les neurofibres ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'électromyographie (EMG) et les potentiels évoqués sont couramment utilisés." } }, { "@type": "Question", "name": "Les IRM sont-elles utiles pour les neurofibres ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les IRM peuvent visualiser les lésions nerveuses et les anomalies des neurofibres." } }, { "@type": "Question", "name": "Quels signes indiquent une atteinte des neurofibres ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs, des engourdissements ou une faiblesse musculaire peuvent indiquer une atteinte." } }, { "@type": "Question", "name": "Comment évaluer la conduction nerveuse ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de conduction nerveuse mesurent la vitesse des signaux dans les neurofibres." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une neuropathie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, picotements, faiblesse musculaire et perte de sensation." } }, { "@type": "Question", "name": "Comment se manifeste une neuropathie périphérique ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle se manifeste par des douleurs, des engourdissements et des réflexes diminués." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de neurofibres ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de neurofibres affectées (sensitives, motrices)." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans lésions visibles ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes peuvent survenir sans lésions visibles sur les examens d'imagerie." } }, { "@type": "Question", "name": "Les symptômes s'aggravent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Dans certains cas, les symptômes peuvent s'aggraver progressivement sans traitement." } }, { "@type": "Question", "name": "Comment prévenir les neuropathies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie sain, contrôler le diabète et éviter les toxines peuvent aider." } }, { "@type": "Question", "name": "L'exercice régulier aide-t-il à prévenir les neuropathies ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier améliore la circulation sanguine et la santé nerveuse." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles les neurofibres ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en vitamines B peut soutenir la santé nerveuse." } }, { "@type": "Question", "name": "Fumer augmente-t-il le risque de neuropathie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut endommager les vaisseaux sanguins et affecter les nerfs." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les neurofibres ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut exacerber les symptômes nerveux et affecter la santé globale." } }, { "@type": "Question", "name": "Quels traitements existent pour les neuropathies ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent médicaments, thérapies physiques et interventions chirurgicales." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils soulager la douleur nerveuse ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des analgésiques et des anticonvulsivants sont souvent prescrits pour soulager la douleur." } }, { "@type": "Question", "name": "La physiothérapie aide-t-elle les patients ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut améliorer la force musculaire et la coordination." } }, { "@type": "Question", "name": "Quand envisager une intervention chirurgicale ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une chirurgie est envisagée si les symptômes sont graves et ne répondent pas aux traitements conservateurs." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements varie selon la cause et la gravité de la neuropathie." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une neuropathie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des blessures et des problèmes d'équilibre." } }, { "@type": "Question", "name": "La neuropathie peut-elle entraîner des amputations ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des lésions nerveuses sévères peuvent augmenter le risque d'amputation, surtout chez les diabétiques." } }, { "@type": "Question", "name": "Les troubles de la marche sont-ils une complication ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la neuropathie peut affecter la coordination et entraîner des troubles de la marche." } }, { "@type": "Question", "name": "Peut-on développer une dépression à cause de la neuropathie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la douleur chronique et les limitations fonctionnelles peuvent contribuer à la dépression." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque de neuropathie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le diabète, l'alcoolisme, les infections et certaines maladies auto-immunes." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de neuropathie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de neuropathie augmente avec l'âge en raison de la dégradation nerveuse." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de neuropathie peuvent augmenter le risque individuel." } }, { "@type": "Question", "name": "Le diabète est-il un facteur de risque majeur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète est l'un des principaux facteurs de risque de neuropathie périphérique." } }, { "@type": "Question", "name": "Les carences nutritionnelles augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des carences en vitamines B et en acide folique peuvent augmenter le risque de neuropathie." } } ] } ] }

Sources (10000 au total)

Tocolytics for delaying preterm birth: a network meta-analysis (0924).

Preterm birth is the leading cause of death in newborns and children. Tocolytic drugs aim to delay preterm birth by suppressing uterine contractions to allow time for administration of corticosteroids... To estimate relative effectiveness and safety profiles for different classes of tocolytic drugs for delaying preterm birth, and provide rankings of the available drugs.... We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov (21 April 2021) and reference lists of retrieved studies.... We included all randomised controlled trials assessing effectiveness or adverse effects of tocolytic drugs for delaying preterm birth. We excluded quasi- and non-randomised trials. We evaluated all st... At least two review authors independently assessed the trials for inclusion and risk of bias, and extracted data. We performed pairwise and network meta-analyses, to determine the relative effects and... This network meta-analysis includes 122 trials (13,697 women) involving six tocolytic classes, combinations of tocolytics, and placebo or no treatment. Most trials included women with threatened prete... Compared with placebo or no tocolytic treatment, all tocolytic drug classes that we assessed (betamimetics, calcium channel blockers, magnesium sulphate, oxytocin receptor antagonists, nitric oxide do...

Pharmacological treatments in panic disorder in adults: a network meta-analysis.

A panic attack is a discrete period of fear or anxiety that has a rapid onset and reaches a peak within 10 minutes. The main symptoms involve bodily systems, such as racing heart, chest pain, sweating... To compare, via network meta-analysis, individual drugs (antidepressants and benzodiazepines) or placebo in terms of efficacy and acceptability in the acute treatment of panic disorder, with or withou... We searched the Cochrane Common Mental Disorders Specialised Register, CENTRAL, CDSR, MEDLINE, Ovid Embase and PsycINFO to 26 May 2022.... We included randomised controlled trials (RCTs) of people aged 18 years or older of either sex and any ethnicity with clinically diagnosed panic disorder, with or without agoraphobia. We included tria... Two authors independently screened titles/abstracts and full texts, extracted data and assessed risk of bias. We analysed dichotomous data and continuous data as risk ratios (RRs), mean differences (M... Overall, we included 70 trials in this review. Sample sizes ranged between 5 and 445 participants in each arm, and the total sample size per study ranged from 10 to 1168. Thirty-five studies included ... In terms of efficacy, SSRIs, SNRIs (venlafaxine), TCAs, MAOIs and BDZs may be effective, with little difference between classes. However, it is important to note that the reliability of these findings...

Thresholds for surfactant use in preterm neonates: a network meta-analysis.

To perform a network meta-analysis of randomised controlled trials of different surfactant treatment strategies for respiratory distress syndrome (RDS) to assess if a certain fraction of inspired oxyg... Systematic review and network meta-analysis using Bayesian analysis of randomised trials of prophylactic versus selective surfactant for RDS.... Cochrane Central Register of Controlled Trials, MEDLINE, Embase and Science Citation Index Expanded.... Randomised trials including infants under 32 weeks of gestational age.... Intratracheal surfactant, irrespective of type or dose.... Our primary outcome was neonatal mortality, compared between groups treated with selective surfactant therapy at different thresholds of FiO... Of 4643 identified references, 14 studies involving 5298 participants were included. We found no statistically significant differences between 30%, 40% and 50% FiO... Our results do not show a clear benefit of surfactant treatment at any threshold of FiO... CRD42020166620....

Common bile duct stones management: A network meta-analysis.

Timely management is critical for treating symptomatic common bile duct (CBD) stones; however, a single optimal management strategy has yet to be defined in the acute care setting. Consequently, this ... PubMed, SCOPUS, MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were methodically queried for articles from 2010 to 2021. The search terms were a combination of medical subject hea... A total of 16 studies (8,644 participants) addressing the LOS and 41 studies (19,756 participants) addressing postprocedural complications were included in the analysis. The one-stage approaches were ... This network meta-analysis suggests that both laparoscopic CBD exploration and intraoperative ERCP have equally good outcomes and provide a preferable single-anesthesia patient pathway with a shorter ... Systematic Review/Meta Analysis; Level III....

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.

In recent years a broader range of immunomodulatory and immunosuppressive treatment options have emerged for people with progressive forms of multiple sclerosis (PMS). While consensus supports these o... To compare through network meta-analysis the efficacy and safety of alemtuzumab, azathioprine, cladribine, cyclophosphamide, daclizumab, dimethylfumarate, diroximel fumarate, fingolimod, fludarabine, ... We searched CENTRAL, MEDLINE, and Embase up to August 2022, as well as ClinicalTrials.gov and the WHO ICTRP.... Randomised controlled trials (RCTs) that studied one or more treatments as monotherapy, compared to placebo or to another active agent, for use in adults with PMS.... Two review authors independently selected studies and extracted data. We performed data synthesis by pair-wise and network meta-analysis. We assessed the certainty of the body of evidence according to... We included 23 studies involving a total of 10,167 participants. The most frequent (39% of studies) reason for a rating of high risk of bias was sponsor role in study authorship and data management an... The number of people with PMS with relapses is probably slightly reduced with rituximab at two years, and interferon beta-1b at three years, compared to placebo. Both drugs are also probably associate...

Moist dressings in the treatment of pressure injuries: A network meta-analysis.

The aim of this network meta-analysis is to analyze the difference in therapeutic effects between moist dressings and traditional dressings in the treatment of pressure injury (PI), explore the healin... The incidence of pressure injury is high and the burden of disease is high, but there is no consensus on how to choose moist dressing treatment.... A systematic review with network meta-analysis was performed.... We searched the Chinese Biomedicine Literature Database and China National Knowledge Infrastructure, Wanfang Database, VIP database, PubMed, Web of Science, EMBASE.com, CENTRAL (Cochrane Central Regis... R studio software and Stata 16.0 software were used to compare different moist dressings and traditional dressings.... 41 RCTs of moist dressings in the treatment of PI were included. A total of seven kinds of moist dressings, Vaseline gauze and traditional gauze dressing were involved. All RCTs were at a medium to hi... The effect of moist dressings in treating PI is more advantageous than traditional dressings. However, in terms of direct cost and the number of dressings changes, more research is needed to improve t... This study is a network meta-analysis, which does not require the participation of patients and the public....